<div id="readability-page-1" class="page"><p>GatePass Capital LLC purchased a new position in shares of  The Oncology Institute, Inc. (NASDAQ:TOI - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities &amp; Exchange Commission. The firm purchased 360,000 shares of the company's stock, valued at approximately $1,282,000. GatePass Capital LLC owned 0.37% of Oncology Institute as of its most recent SEC filing.</p><div><p><span></span><span>Get <strong>Oncology Institute</strong> alerts:</span></p></div><p>Several other hedge funds have also modified their holdings of TOI. Goldman Sachs Group Inc. purchased a new position in  Oncology Institute in the first quarter valued at $131,000.  Geode Capital Management LLC boosted its holdings in  Oncology Institute by 231.7% in the second quarter. Geode Capital Management LLC now owns 1,279,443 shares of the company's stock valued at $2,623,000 after purchasing an additional 893,696 shares during the period.  Cetera Investment Advisers boosted its holdings in  Oncology Institute by 35.0% in the second quarter. Cetera Investment Advisers now owns 17,545 shares of the company's stock valued at $36,000 after purchasing an additional 4,545 shares during the period.  JPMorgan Chase &amp; Co. boosted its holdings in  Oncology Institute by 51,631.5% in the second quarter. JPMorgan Chase &amp; Co. now owns 27,935 shares of the company's stock valued at $57,000 after purchasing an additional 27,881 shares during the period.  Finally, New York State Common Retirement Fund purchased a new position in  Oncology Institute in the second quarter valued at $92,000. 36.86% of the stock is currently owned by institutional investors and hedge funds. </p><h2>Analyst Upgrades and Downgrades</h2><p>A number of research analysts recently issued reports on TOI shares. Weiss Ratings  reiterated a &#34;sell (d-)&#34; rating on shares of Oncology Institute in a report on Monday, April 20th. B. Riley Financial lifted their target price on Oncology Institute from $6.00 to $8.00 and gave the company a &#34;buy&#34; rating in a report on Friday, March 13th. Needham &amp; Company LLC  reiterated a &#34;buy&#34; rating and issued a $5.00 target price on shares of Oncology Institute in a report on Monday, March 9th. Finally, BTIG Research  reiterated a &#34;buy&#34; rating and issued a $7.00 target price on shares of Oncology Institute in a report on Monday, March 9th. Four equities research analysts have rated the stock with a Buy rating and one  has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $7.00.</p><p><b>Read Our Latest Research Report on TOI</b></p><h2>Insider Transactions at Oncology Institute</h2><p>In other news, Director Mohit Kaushal sold 38,433 shares of Oncology Institute stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of $3.50, for a total transaction of $134,515.50. Following the sale, the director owned 172,583 shares in the company, valued at approximately $604,040.50. The trade was a 18.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Jorey Chernett bought 33,500 shares of the business's stock in a transaction dated Wednesday, May 20th. The shares were purchased at an average price of $4.07 per share, for a total transaction of $136,345.00. Following the transaction, the insider directly owned 10,567,858 shares of the company's stock, valued at approximately $43,011,182.06. This represents a 0.32% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have bought 637,485 shares of company stock worth $2,038,896 in the last quarter. Insiders own  8.50% of the company's stock. </p><h2>Oncology Institute Stock Performance</h2><p>TOI opened at $4.59 on Tuesday. The business's 50-day simple moving average is $3.54 and its 200-day simple moving average is $3.33. The Oncology Institute, Inc. has a one year low of $2.02 and a one year high of $4.88. The stock has a market capitalization of $453.68 million, a P/E ratio of -12.41 and a beta of 0.33. </p><p>Oncology Institute (NASDAQ:TOI - Get Free Report) last posted its earnings results on Thursday, May 7th. The company reported ($0.02) EPS for the quarter, topping analysts' consensus estimates of ($0.07) by $0.05. The firm had revenue of $147.44 million for the quarter, compared to analyst estimates of $142.10 million.  On average, equities research analysts forecast that  The Oncology Institute, Inc. will post -0.2 EPS for the current fiscal year. </p><h2>Oncology Institute Profile</h2> (Free Report)<p>The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials &amp; Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Oncology Institute</li><li>SpaceX Gets the Attention, But These 4 Stocks Could Get the Returns</li><li>Microsoft Stock Discount May Be Ending as AI Catalysts Build</li><li>Apparel Earnings Winners and Losers: Ralph Lauren Takes Off</li><li>Why Walmart, Target and TJX Got Such Different Reactions After Earnings</li></ul><p><strong>Want to see what other hedge funds are holding TOI?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Oncology Institute, Inc. (NASDAQ:TOI - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE9J?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE9J"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Oncology Institute Right Now?</h2><p>Before you consider Oncology Institute, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncology Institute wasn't on the list.</p><p>While Oncology Institute currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

SBIO

<p>GatePass Capital LLC has invested $1.28 million in The Oncology Institute, Inc. by acquiring 360,000 shares. Other hedge funds have also adjusted their holdings in TOI. Analysts have mixed ratings on the stock, with a consensus rating of 'Moderate Buy' and a target price of $7.00. The stock opened at $4.59, with a market cap of $453.68 million. The Oncology Institute reported better-than-expected earnings, with revenue of $147.44 million for the last quarter.</p>

Market Beat

Oncology Institute

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

Direxion S&P Biotech Bull 3X

VG Health

SPDR S&P Biotech

Health Care Select Sector SPDR

Invesco Biotechnology & Genome ETF

SPDR S&P Health

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

iShares Global Healthcare

iShares US Healthcare Providers

iShares Biotechnology ETF

Goldman Sachs

JPMorgan Chase

Oncology Institute - CW22

GS Hldg R

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

B Riley Financial Pref Share RILYL 7.375 Perp 09/04/25 B

B Riley Financial Pref Share RILYG 7.25 12/21/27

B Riley Financial Pref Share RILYN 6.5 09/30/2026

B Riley Financial Pref Share RILYK 5.5 03/31/26

B Riley Financial Pref Share RILYP 6.875 Perp 10/07/24

B Riley Financial Pref Share RILYZ 5.25 08/31/28

B Riley Financial Pref Share RILYT 6.0 01/31/28

GatePass Capital LLC Invests $1.28 Million in The Oncology Institute, Inc. $TOI